Steven Marotta
Stock Analyst at CL King
(0.53)
# 4,257
Out of 5,238 analysts
15
Total ratings
37.5%
Success rate
-15.08%
Average return
Main Sectors:
Stocks Rated by Steven Marotta
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GIII G-III Apparel Group | Downgrades: Neutral | n/a | $31.76 | - | 1 | Dec 1, 2022 | |
| SHOO Steven Madden | Upgrades: Buy | n/a | $40.61 | - | 1 | Sep 28, 2022 | |
| CTKB Cytek Biosciences | Initiates: Overweight | $28 | $4.61 | +507.38% | 1 | Aug 17, 2021 | |
| AVTR Avantor | Upgrades: Overweight | $32 → $41 | $8.31 | +393.38% | 3 | Aug 2, 2021 | |
| CAL Caleres | Upgrades: Buy | $29 | $13.50 | +114.81% | 2 | Jun 1, 2021 | |
| CROX Crocs | Downgrades: Neutral | n/a | $103.63 | - | 3 | Jul 17, 2020 | |
| GCO Genesco | Upgrades: Buy | n/a | $34.89 | - | 4 | Jan 21, 2020 |
G-III Apparel Group
Dec 1, 2022
Downgrades: Neutral
Price Target: n/a
Current: $31.76
Upside: -
Steven Madden
Sep 28, 2022
Upgrades: Buy
Price Target: n/a
Current: $40.61
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Overweight
Price Target: $28
Current: $4.61
Upside: +507.38%
Avantor
Aug 2, 2021
Upgrades: Overweight
Price Target: $32 → $41
Current: $8.31
Upside: +393.38%
Caleres
Jun 1, 2021
Upgrades: Buy
Price Target: $29
Current: $13.50
Upside: +114.81%
Crocs
Jul 17, 2020
Downgrades: Neutral
Price Target: n/a
Current: $103.63
Upside: -
Genesco
Jan 21, 2020
Upgrades: Buy
Price Target: n/a
Current: $34.89
Upside: -